MRK Merck & Co Inc

  1. Stocks
  2. Healthcare
  3. NYSE: MRK

Price (delayed)

$144.3

Market cap

$356.01B

P/E Ratio

113.62

Dividend/share

$3.4

EPS

$1.27

Enterprise value

$403.07B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 53

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives ...

Highlights
The revenue has grown by 4.6% YoY
MRK's quick ratio is down by 10% year-on-year but it is up by 8% since the previous quarter
The P/E is 183% higher than the last 4 quarters average of 40.1 and 52% higher than the 5-year quarterly average of 74.7
The net income has dropped by 81% year-on-year and by 64% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.merck.com
Peers: PFE JNJ LLY BMY

Key stats

What are the main financial stats of MRK

MRK stock price

How has the Merck stock price performed over time
Intraday
0.34%
1 week
-3.01%
1 month
-4.84%
1 year
61.21%
YTD
37.09%
QTD
-0.7%

Financial performance

How have Merck's revenue and profit performed over time
Revenue
$66.57B
Gross profit
$48.57B
Operating income
$6.38B
Net income
$3.17B
Gross margin
73%
Net margin
4.8%
The net income has dropped by 81% year-on-year and by 64% since the previous quarter
MRK's net margin has dropped by 81% year-on-year and by 65% since the previous quarter
Merck's operating margin has shrunk by 68% YoY and by 47% QoQ
Merck's operating income has plunged by 67% YoY and by 47% from the previous quarter

Price vs fundamentals

How does MRK's price correlate with its fundamentals

Growth

What is Merck's growth rate over time

Valuation

What is Merck stock price valuation
MRK P/E details
P/E
113.62
P/B
8.5
P/S
5.35
EV/EBIT
52.39
EV/EBITDA
27.97
EV/Sales
6.05
The P/E is 183% higher than the last 4 quarters average of 40.1 and 52% higher than the 5-year quarterly average of 74.7
The EPS has plunged by 80% YoY and by 64% from the previous quarter
The price to book (P/B) is 47% higher than the last 4 quarters average of 5.8 and 44% higher than the 5-year quarterly average of 5.9
Merck's equity has decreased by 14% YoY and by 9% from the previous quarter
MRK's P/S is 27% above its last 4 quarters average of 4.2 and 24% above its 5-year quarterly average of 4.3
The revenue has grown by 4.6% YoY

Efficiency

How efficient is Merck business performance
The company's return on assets has shrunk by 83% YoY and by 66% QoQ
Merck's ROE has plunged by 81% YoY and by 63% from the previous quarter
The ROIC has shrunk by 70% YoY and by 45% QoQ
The ROS has plunged by 64% YoY and by 42% from the previous quarter

Dividends

What is MRK's dividend history
Dividend details
DPS
$3.4
Dividend yield
2.36%
Payout ratio
267.7%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Merck financials performed over time
The total assets is 48% more than the total liabilities
Merck's total liabilities has increased by 28% YoY and by 6% QoQ
The total assets has grown by 10% YoY
MRK's debt is 29% greater than its equity
The debt to equity has soared by 79% YoY and by 21% from the previous quarter
MRK's debt has surged by 52% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.